Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia

Inclusion Criteria

• •Diagnosis of BCR-ABL positive CML in early chronic phase CML. Except for hydroxyurea, patients must have received no or minimal prior therapy, defined as \<2 weeks (14 days) of prior FDA approved TKI.
• •ECOG performance of 0-2
• •Adequate end organ function, defined as the following: total bilirubin \<1.5x ULN, SGPT \<2.5x ULN, creatinine \<1.5x ULN.
• •Patients must sign an informed consent indicating they are aware of the investigational nature of this study.